Eisai Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EISAI INC, and when can generic versions of EISAI INC drugs launch?
EISAI INC has eleven approved drugs.
There are twelve US patents protecting EISAI INC drugs.
There are three hundred and ten patent family members on EISAI INC drugs in forty-two countries and thirty-nine supplementary protection certificates in eighteen countries.
Summary for Eisai Inc
International Patents: | 310 |
US Patents: | 12 |
Tradenames: | 8 |
Ingredients: | 7 |
NDAs: | 11 |
Drug Master File Entries: | 1 |
Drugs and US Patents for Eisai Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eisai Inc | LUSEDRA | fospropofol disodium | SOLUTION;INTRAVENOUS | 022244-001 | Dec 12, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | 10,188,652 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-002 | Apr 7, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | HEXALEN | altretamine | CAPSULE;ORAL | 019926-001 | Dec 26, 1990 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eisai Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-002 | Nov 14, 2008 | 8,076,362*PED | ⤷ Try a Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 5,985,864 | ⤷ Try a Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 4,895,841 | ⤷ Try a Trial |
Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | 8,097,648 | ⤷ Try a Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 6,140,321 | ⤷ Try a Trial |
Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | 6,740,669*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
International Patents for Eisai Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Tunisia | 2013000119 | ⤷ Try a Trial |
Japan | 5086304 | ⤷ Try a Trial |
Singapore | 10202100272R | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2005063713 | ⤷ Try a Trial |
Hungary | 227912 | ⤷ Try a Trial |
South Korea | 20050108426 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eisai Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0994864 | SPC/GB07/041 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015 |
1087960 | 1191021-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT EU/1/11/678/001-002, 2011-03-17 EG |
1087960 | C300493 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317 |
1415987 | CA 2015 00053 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT, HERUNDER LEVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601 |
1415987 | 122015000083 | Germany | ⤷ Try a Trial | PRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528 |
1415987 | 15C0070 | France | ⤷ Try a Trial | PRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.